External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>TBPH prioritizes shareholder value and is trading at a discount to its NAV</li><li>The company is an attractive investment opportunity for value investors</li><li>TBPH has a strong focus on maximizing shareholder value, valuable assets, and potential for significant upside</li></ul>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

TBPH prioritizes shareholder value and is trading at a discount to its NAVThe company is an attractive investment opportunity for value investorsTBPH has a strong focus on maximizing shareholder value, valuable assets, and potential for significant upsideThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Theravance Biopharma Inc (TBPH) - Tuesday, Jul 9, 2024

Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

<a href="https://www.smartkarma.com/entities/870" target="_blank" data-smartkarma-citation="entities:870:1">Mylan Nv (MYL US)</a> stock has seen some downward pressure since 2015 after the increased capital expenditure and debt load for acquisitions pressurized some financial efficiency measures like ROIC. While the company's debt to equity ratio at present is higher than the industry average (due to recent acquisitions), current ratio and quick ratio are comparable to the industry average. About US$2.4 billion of debt is due in 2018 and the reduction of the debt, and synergies and increase sales from recent large acquisitions are expected to improve operating cash flow growth, profit margin% and ROIC in the next 3 to 4 years.We consider <a href="https://www.smartkarma.com/entities/870" target="_blank" data-smartkarma-citation="entities:870:1">Mylan Nv (MYL US)</a> common stock as undervalued at present. Our first price target by enterprise DCF method is US$46. The stock also appears undervalued by relative valuation measures like forward EV/EBITDA.

Mylan Nv (MYL US) stock has seen some downward pressure since 2015 after the increased capital expenditure and debt load for acquisitions pressurized some financial efficiency measures like ROIC. While the company's debt to equity ratio at present is higher than the industry average (due to recent acquisitions), current ratio and quick ratio are comparable to the industry average. About US$2.4 billion of debt is due in 2018 and the reduction of the debt, and synergies and increase sales from recent large acquisitions are expected to improve operating cash flow growth, profit margin% and ROIC in the next 3 to 4 years.We consider Mylan Nv (MYL US) common stock as undervalued at present. Our first price target by enterprise DCF method is US$46. The stock also appears undervalued by relative valuation measures like forward EV/EBITDA. 

Mylan N.V. (MYL US): Another Contrarian Pharmaceutical Investment

United States

Theravance Biopharma Inc focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Theravance Biopharma (TBPH US)

Theravance Biopharma Inc (TBPH) - Tuesday, Jul 9, 2024

TBPH prioritizes shareholder value and is trading at a discount to its NAV. The company is an attractive investment opportunity for value investors

Value Investors Club

Mylan N.V. (MYL US): Another Contrarian Pharmaceutical Investment

Mylan Nv (MYL US) stock has seen some downward pressure since 2015 after the increased capital expenditure and debt load for acquisitions...

Dr. Bhavneesh Sharma, MD, MBA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)